Pharmacological intervention targeting chemokines produced by cDCs and T cells, such as CXCL9, CXCL10, and CCL25, may be beneficial for patients with type 1 AIP, in addition to pre-existing SLE biologics targeting pDCs and type I IFNs. This evidence concerns the gene CXCL9 and systemic lupus erythematosus.